Navigation Links
Vantia Therapeutics Raises £4 Million to Fund Clinical Development of its Lead Compounds
Date:7/6/2011

benign prostatic hypertrophy (BPH). This population forms the largest part of the nocturia market and represents the greatest unmet need. The results of this trial are expected in the second half of 2011 and will be used to support the design of pivotal clinical trials. Data from previous clinical trials, presented at the American Urological Association meeting in 2010, demonstrated a dose-dependent pharmacological effect and suggested that VA106483 has the potential to be an effective and well tolerated antidiuretic for the treatment of nocturia.

About Vantia Therapeutics:

Vantia Therapeutics is an emerging pharmaceutical company developing novel, small molecule drugs targeting large areas of unmet medical need. Its strong clinical pipeline includes VA106483 for nocturia and VA111913 for dysmenorrhoea, which directly target indications that together affect many millions of people, are poorly treated and represent billion dollar markets. Vantia's strategy is to develop its proprietary drug candidates through Phase II clinical testing and then commercialise through partnerships. The Company was founded in 2008 and is backed by specialist life science investors Novo A/S, SV Life Sciences and MVM Life Science Partners.

http://www.vantiatherapeutics.com

VA106483 - Nocturia

VA106483 is a novel small molecule drug candidate discovered by Vantia Therapeutics and is in Phase II trials to treat nocturia, a common condition that causes sufferers to wake frequently during the night in order to urinate, thus interrupting sleep. VA106483 acts directly in the collecting ducts of the kidney by binding to vasopressin V2 receptors.

Nocturia increases markedly with age and is often the presenting symptom in men with benign prostatic hypertrophy (BPH), affecting at least 70% of the more than 15 million BPH patients in the United States and Europe. Treatments for
'/>"/>

SOURCE Vantia Therapeutics
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Vantia Therapeutics Pipeline Continues to Mature
2. Vantia Therapeutics Lead Candidate VA106483 Demonstrates Positive Anti-diuretic Effect in Phase IIa Trial in Nocturia
3. Vantia Therapeutics Lead Candidate VA106483 Enters Phase IIb Trial for Nocturia
4. Vicus Therapeutics to Present at the 234th American Chemical Society National Meeting in Boston, MA
5. Allos Therapeutics Initiates Study of PDX in Patients with Cutaneous T-Cell Lymphoma
6. Amicus Therapeutics Announces Second Quarter 2007 Financial Results
7. TorreyPines Therapeutics Completes Patient Enrollment in Phase IIb Clinical Trial of Tezampanel for the Treatment of Acute Migraine Headache
8. CV Therapeutics Announces Eight Abstracts Accepted for Presentation at the European Society of Cardiology Congress 2007
9. Pharmacopeia Assists the World Health Organization in the Discovery of Novel Therapeutics for the Treatment of Malaria
10. Protalix BioTherapeutics Treats First Patient in Phase III Clinical Trial of prGCD
11. TorreyPines Therapeutics Initiates a Phase I Multiple Dose Clinical Trial of Tezampanel
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/30/2014)... Sept. 30, 2014 Aileron Therapeutics, Inc. ... Global Markets Direct,s, ,Aileron Therapeutics, Inc. - ... of the Aileron Therapeutics, Inc.,s pharmaceutical research and ... on the current therapeutic developmental pipeline of Aileron ... stages, therapeutics assessment by drug target, mechanism of ...
(Date:9/30/2014)... , Sept. 30, 2014  Decision Resources Group finds that ... Australia , China , ... expand at a strong rate through 2023. Dental implant procedure volumes ... as patient awareness rises. Other key findings from Decision ... dental implant market: , Dental implant penetration: Penetration ...
(Date:9/30/2014)... 2014 According to ... by Product [Enzymes (Glycosyltransferase, Neuraminidase, Glycosidase), Instruments ... Application (Immunology, Oncology) & by End User ... MarketsandMarkets, provides a detailed overview of the ... trends, and strategies impacting the global glycomics ...
Breaking Medicine Technology:Aileron Therapeutics, Inc. - Product Pipeline Review - 2014 2Aileron Therapeutics, Inc. - Product Pipeline Review - 2014 3Asia Pacific Dental Implant Market Will Grow at a Strong Rate Through 2023 2Asia Pacific Dental Implant Market Will Grow at a Strong Rate Through 2023 3Glycobiology / Glycomics Market Worth $928.11 Million by 2019 2Glycobiology / Glycomics Market Worth $928.11 Million by 2019 3Glycobiology / Glycomics Market Worth $928.11 Million by 2019 4
... and Company) (NYSE: BDX ), a global medical technology company,announced today that ... Credit Suisse 2007 Healthcare Conference ... (ET), Lazard Capital ... November 27, 2007 - 9:00 a.m. (ET) A live webcast ...
... Golimumab Achieved Primary and Major Secondary Endpoints in ... Trial Completed to Date in Psoriatic Arthritis, ... arthritis,receiving monthly subcutaneous (SC) injections of golimumab (CNTO ... and skin,manifestations of the disease, according to findings ...
Cached Medicine Technology:Phase 3 Data Show New Anti-TNF, Golimumab, Significantly Improved Arthritis, Skin and Nail Manifestations in Patients with Psoriatic Arthritis 2Phase 3 Data Show New Anti-TNF, Golimumab, Significantly Improved Arthritis, Skin and Nail Manifestations in Patients with Psoriatic Arthritis 3Phase 3 Data Show New Anti-TNF, Golimumab, Significantly Improved Arthritis, Skin and Nail Manifestations in Patients with Psoriatic Arthritis 4Phase 3 Data Show New Anti-TNF, Golimumab, Significantly Improved Arthritis, Skin and Nail Manifestations in Patients with Psoriatic Arthritis 5Phase 3 Data Show New Anti-TNF, Golimumab, Significantly Improved Arthritis, Skin and Nail Manifestations in Patients with Psoriatic Arthritis 6Phase 3 Data Show New Anti-TNF, Golimumab, Significantly Improved Arthritis, Skin and Nail Manifestations in Patients with Psoriatic Arthritis 7Phase 3 Data Show New Anti-TNF, Golimumab, Significantly Improved Arthritis, Skin and Nail Manifestations in Patients with Psoriatic Arthritis 8
(Date:10/1/2014)... (PRWEB) October 01, 2014 ... networking and relationship-marketing firm, announced today the ... Executive® and Project of the Year Awards ... makers representing organizations in financial services, commercial, ... large-scale technology endeavors that address key issues ...
(Date:10/1/2014)... October 01, 2014 Beverly Hills licensed ... Mojas is celebrating 20 years of private practice in ... of people to achieve greater joy and fulfillment in ... of warning signs and suggestions for anyone who suspects ... explains: “Believe it or not, it’s not always ...
(Date:10/1/2014)... (PRWEB) October 01, 2014 NoteSwift Inc., ... EHR versions 10.0, 12.1 and 13.0. NoteSwift is the ... as commands to navigate and document clinical information at ... provider spends creating a patient note by more than ... of the major pain points providers state impedes EHR ...
(Date:10/1/2014)... in Bahir Dar, Ethiopia, at the occasion of ... gathered some 150 African and international leishmaniasis experts, ... safety and efficacy monitoring plan, carried out ... Sudan, Uganda, and Ethiopia, were presented to key ... to treatment of kala-azar with the combination of ...
(Date:10/1/2014)... 01, 2014 Dr. Saj Jivraj, one ... prosthodontists, is traveling to Chennai, India, tomorrow to speak ... 2 and 3. , Dr. Jivraj is founder of ... Oxnard, Calif., and one of the world’s foremost prosthodontists, ... replacement. He is speaking to the Indian Society of ...
Breaking Medicine News(10 mins):Health News:T.E.N. Announces Nominees for the 2014 ISE® North America Awards; People’s Choice Award voting now open to industry at large 2Health News:T.E.N. Announces Nominees for the 2014 ISE® North America Awards; People’s Choice Award voting now open to industry at large 3Health News:T.E.N. Announces Nominees for the 2014 ISE® North America Awards; People’s Choice Award voting now open to industry at large 4Health News:T.E.N. Announces Nominees for the 2014 ISE® North America Awards; People’s Choice Award voting now open to industry at large 5Health News:T.E.N. Announces Nominees for the 2014 ISE® North America Awards; People’s Choice Award voting now open to industry at large 6Health News:T.E.N. Announces Nominees for the 2014 ISE® North America Awards; People’s Choice Award voting now open to industry at large 7Health News:Prominent Beverly Hills Psychologist Dr. Kathleen Mojas Celebrating 20 Years in Private Practice Identifies Common Warning Signs That You May Be In a Toxic Relationship. 2Health News:Prominent Beverly Hills Psychologist Dr. Kathleen Mojas Celebrating 20 Years in Private Practice Identifies Common Warning Signs That You May Be In a Toxic Relationship. 3Health News:NoteSwift Joins Allscripts Developer Program 2Health News:NoteSwift Joins Allscripts Developer Program 3Health News:Results of large-scale roll out of combination treatment for kala-azar in Eastern Africa 2Health News:One of Woodland Hills’ Top Cosmetic Dentists Speaking to Indian Society of Oral Implantologists Tomorrow 2Health News:One of Woodland Hills’ Top Cosmetic Dentists Speaking to Indian Society of Oral Implantologists Tomorrow 3Health News:One of Woodland Hills’ Top Cosmetic Dentists Speaking to Indian Society of Oral Implantologists Tomorrow 4Health News:One of Woodland Hills’ Top Cosmetic Dentists Speaking to Indian Society of Oral Implantologists Tomorrow 5
... directs the University of Southern California Center for ... to evaluate robots as exercise coaches for adults of ... The effort, entitled "Robot Motivator: Towards Adaptive Health ... of virtual social characters on people,s motivation to exercise. ...
... , , - ... 41% from 31% in Q3 2008 , - Q3 2009 Operating ... 2009 Pre-tax Income Increases 168% from same period in 2008 , ... LWAY ), makers of the nutritious, probiotic dairy beverage called kefir, ...
... of this group with better preventive care, , THURSDAY, Nov. ... health measures can prolong lives, but only 25 percent of ... getting these recommended screenings, a new report shows. , Prepared ... and the American Medical Association, the report also lays out ...
... no more likely to have post-operative complications than those ... uterine fibroids, according to a study at Henry Ford ... fibroids, leaving the uterus intact and preserving the ability ... obese patient can present difficulties for the most experienced ...
... ... in Buffalo, NY, launched their revitalized and interactive website Monday, November 16, 2009. The ... . The project was initiated to provide users with an enhanced shopping and ordering ... (PRWEB) November 18, ...
... MELVILLE, N.Y., Nov. 19 Long Island IVF, a full ... patients achieve successful pregnancies, is now offering a new program ... treatment. Through this program and a partnership with In Vitro ... amount of money couples pay for their comprehensive treatment plans ...
Cached Medicine News:Health News:Lifeway Foods Reports Record 3rd Quarter 2009 Revenues and Earnings Results 2Health News:Lifeway Foods Reports Record 3rd Quarter 2009 Revenues and Earnings Results 3Health News:Lifeway Foods Reports Record 3rd Quarter 2009 Revenues and Earnings Results 4Health News:Lifeway Foods Reports Record 3rd Quarter 2009 Revenues and Earnings Results 5Health News:Lifeway Foods Reports Record 3rd Quarter 2009 Revenues and Earnings Results 6Health News:Lifeway Foods Reports Record 3rd Quarter 2009 Revenues and Earnings Results 7Health News:Lifeway Foods Reports Record 3rd Quarter 2009 Revenues and Earnings Results 8Health News: Too Few Older Adults Get Recommended Screenings 2Health News: Too Few Older Adults Get Recommended Screenings 3Health News:Patient's weight not linked to success of fibroid surgery 2Health News:Great Customer Service Just Got Better as Emedco Announces the Launch of their Completely Updated and Enhanced Website 2Health News:Great Customer Service Just Got Better as Emedco Announces the Launch of their Completely Updated and Enhanced Website 3Health News:Long Island IVF to Offer IVF Financial Share Program, Limiting Costs and Providing Refunds if IVF is Not Successful 2
... The Crossover system of implants and ... range of posterior rod construct in the ... in this system are available in three ... cross connectors can be used with the ...
Multiwindow transcranial and peripheral Doppler system....
... Multi frequency and multigate ... detection and fitted with ... tests for hemodynamic evaluation. ... as well for routine ...
One channel transcranial Doppler...
Medicine Products: